Please login to the form below

Not currently logged in
Email:
Password:

alteplase

This page shows the latest alteplase news and features for those working in and with pharma, biotech and healthcare.

Biogen hands out $120m upfront for Remedy stroke drug

Biogen hands out $120m upfront for Remedy stroke drug

The US biotech major is paying $120m upfront for rights to the drug, which is vying to be the first new treatment for ischaemic stroke since alteplase - still the only approved

Latest news

  • AZ's Brilinta disappoints in stroke trial AZ's Brilinta disappoints in stroke trial

    Currently the only drug approved for the treatment of ischemic stroke is Genentech's tissue plasminogen activator (tPA) Activase (alteplase), although this remains a controversial therapy as the drug has an

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    as Genentech/Boehringer Ingelheim's Activase/Actilyse (alteplase), but Translational Sciences believes there is significant room for improvement.

  • Lundbeck's desmoteplase flunks phase III stroke trial Lundbeck's desmoteplase flunks phase III stroke trial

    An older thrombolytic called alteplase (tPA) - sold by Genentech as Activase - is already approved to treat stroke, but remains a controversial therapy as the drug has an extremely narrow therapeutic window ... The drug is also easier to administer than

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics